CONMED (NYSE:CNMD) Releases FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 4.540-4.610 for the period, compared to the consensus EPS estimate of 4.540. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Trading Down 1.1%

Shares of CNMD opened at $45.20 on Friday. The business has a 50-day moving average of $47.20 and a 200 day moving average of $41.45. The firm has a market cap of $1.35 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. CONMED has a fifty-two week low of $31.44 and a fifty-two week high of $53.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.69 and a current ratio of 1.48.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.04. The company had revenue of $335.56 million during the quarter, compared to analysts’ expectations of $336.28 million. CONMED had a return on equity of 14.03% and a net margin of 5.36%. The firm’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.08 earnings per share. As a group, research analysts forecast that CONMED will post 4.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. Wall Street Zen upgraded CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Piper Sandler reiterated a “neutral” rating and issued a $45.00 price target (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. JPMorgan Chase & Co. upped their price objective on shares of CONMED from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CONMED presently has an average rating of “Reduce” and a consensus target price of $44.00.

About CONMED

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.